Proteins (and particularly enzymes) are at the heart of most disease processes. The ability to effectively target and inhibit their function within the cell provides an opportunity to mitigate the deleterious outcomes of disease states in humans.Progressing a drug though initial binding assays, animal models and eventual human clinical trials can take 10-15 years and upwards of 800 million dollars.he VDS stream aims to implement a more efficient approach by using software programs to first understand the structural and chemical bonding relationships between the potential inhibitor drug and protein target. From these virtual arrangements, predictions can be made as to which molecules will bind the best while those with low scores are screened out. This method can be easily replicated and scaled up on the computer to analyze hundreds of thousands of molecules. Then the most likely drugs can be purchased and taken to the wet lab to validate their ability to inhibit the protein.